Applications of (S)-3-Amino-3-(4-Bromophenyl)Propionic Acid in Industrial Manufacturing

As an integrated chemical manufacturer with advanced chiral synthesis capabilities, we supply (S)-3-Amino-3-(4-Bromophenyl)Propionic Acid to leading enterprises in several specialized sectors. This enantiomerically pure intermediate supports critical steps in downstream molecular construction, and our facility's batch-to-batch consistency upholds demanding quality and regulatory criteria throughout the industrial supply chain.

1. Chiral Pharmaceutical API Synthesis

Pharmaceutical companies utilize this intermediate during stepwise enantioselective synthesis of active pharmaceutical ingredients, especially those targeting central nervous system and metabolic disorders. Process control and impurity profiles require maintenance of chiral purity from intermediate to API, with heavy reliance on traceable batch records and regulatory filing support.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• Current Good Manufacturing Practice (cGMP, 21 CFR Parts 210 & 211)
• European Pharmacopoeia monograph requirements for intermediates
• US FDA DMF (Drug Master File) listing for upstream intermediates

Typical usage ratio

• Added at 0.5–3.5 molar equivalents per API target step; precise ratio determined by synthetic scheme, enantiomer yield, and process validation outcomes

Downstream process integration

• Employed after early-stage arylation, as a key chiral branching unit in amidation, reductive amination, or carbon-carbon coupling steps during GMP-ready API assembly

Final product types

• Chiral small molecule active pharmaceutical ingredients for neurology, oncology, or metabolic therapy
• Toxicology development compounds for preclinical assessment

2. Peptide-Based Drug Development

Specialty peptide contract manufacturers source this compound as a protected amino acid analogue for constructing peptide chains with enhanced pharmacokinetic stability or receptor selectivity. Custom solid-phase synthesis batches depend on consistent α-chirality to minimize des-isomer formation and guarantee compliance in regulatory filings for clinical candidates.

Industry compliance standards

• USP General Chapter <823> for Radiopharmaceutical Peptides (where applicable)
• ICH Q11 Development and Manufacture of Drug Substances
• Ph. Eur. and USP monograph guidelines for peptide starting materials
• ISO 13485 for peptide APIs intended for diagnostic therapeutics

Typical usage ratio

• Integrated at 1.0 equivalent per coupling site during SPPS cycles; overall percentage in peptide formula ranges between 2–12%, depending on sequence and pharmacological function

Downstream process integration

• Introduced as a non-canonical chiral amino acid during solid-phase peptide assembly via Fmoc/t-Boc strategies; incorporated before selective cleavage, HPLC purification, and lyophilization of crude polypeptide

Final product types

• Peptide-based investigational new drugs (INDs)
• Synthetic peptide reference standards for bioanalytical labs

3. Fine Chemical Building Block for Agrochemical Discovery

Agrochemical R&D laboratories use this chiral intermediate during lead optimization of novel herbicidal or fungicidal molecules. Its substitution pattern and enantioselectivity support SAR (structure-activity relationship) modifications at the molecular scaffold, often impacting bioactivity and selectivity profiles of the agrochemical candidate.

Industry compliance standards

• OECD Principles of Good Laboratory Practice
• Regulation (EC) No 1107/2009 (Plant Protection Product Authorization)
• ISO 17025 for analytical laboratories testing purity and activity
• FAO/WHO Manual on Development and Use of FAO and WHO Specifications for Pesticides

Typical usage ratio

• Variable between 1–10% molecular equivalent in combinatorial libraries; adjusted based on intended structural analogs and screening campaigns

Downstream process integration

• Serves as a chiral auxiliary or core fragment in amide coupling and Suzuki cross-coupling reactions during late-stage lab-scale synthesis of candidate molecules

Final product types

• Herbicide and fungicide research candidates submitted for greenhouse or field bioactivity trials
• Analytical standards for residue analysis

4. Specialty Material Synthesis for Analytical Reagents

Producers of chiral derivatization agents and specialty analytical reagents incorporate this raw material to develop reference standards for chromatography and spectroscopy validation. The stereospecificity and functional group accessibility support the manufacture of calibration compounds used in regulated method development and routine batch QA/QC in the pharmaceutical sector.

Industry compliance standards

• ISO 17034 (General Requirements for Reference Material Producers)
• USP General Chapter <621> Chromatography
• FDA Guidance for Industry: Analytical Procedures and Methods Validation
• Good Laboratory Practice (GLP) standards

Typical usage ratio

• Uses range from 0.2–5% by weight in derivatization agent formulations, commonly depending on the required analytical sensitivity and target analyte concentration

Downstream process integration

• Activated during the synthesis of calibration mixtures and derivatization reagents, following initial protection or modification of the amino group to stabilize the molecule under shipping and storage conditions

Final product types

• Certified chiral reference standards for HPLC/UPLC/MS systems
• Analytical derivatization reagents for enantioselective quantification

5. Custom Intermediate in CNS Active Compound Research

Biotech and contract research organizations engaged in CNS disorder research employ this non-natural amino acid as a fragment for modulation of neurotransmitter analogs. This supports synthesis of tool compounds for receptor binding assays, requiring reliable supply for iterative analog design and lead compound refinement within GLP and IP-protected environments.

Industry compliance standards

• OECD GLP Regulations for Non-Clinical Laboratory Studies
• WIPO patent documentation practices for innovative intermediates
• USP/NF testing and process validation guidelines for intermediate purity
• Internal discovery program compliance (documented traceability, batch records)

Typical usage ratio

• Applied at 1–6% molar load per analog scaffold; actual loading adjusted for targeted receptor binding performance and solubility optimization

Downstream process integration

• Integrated post-core scaffold construction, through N-alkylation, amide bond formation, or Suzuki coupling for side chain modification of neuroactive molecules

Final product types

• Non-GMP CNS drug substance candidates for preclinical pipeline screening
• Custom neuropharmacology tool compounds